Analysts Lift Biogen Targets to $187, $233 and $196 After Q4 Beat
Wedbush lifted its Biogen Inc. price target to $187 from $178 on February 10 after the company beat Q4 and full-year 2025 revenue and earnings expectations while realigning its cost base. RBC raised its target to $233 and BMO to $196 but cited missing revenue growth drivers.
1. Wedbush Raises Price Target
On February 10, Wedbush raised its price target on Biogen Inc. shares to $187 from $178 while maintaining a Neutral rating, highlighting Q4 top- and bottom-line beats and successful cost base realignment.
2. RBC and BMO Update Ratings
RBC Capital lifted its target to $233 from $217 with an Outperform rating, citing stable guidance, commercial execution and expense discipline, while BMO Capital adjusted its target to $196 from $165 and held a Market Perform rating.
3. Q4 Results and Cost Discipline
Biogen’s fiscal Q4 and full-year 2025 results surpassed revenue and earnings expectations, driven by strong performance in its multiple sclerosis and spinal muscular atrophy franchises alongside management’s cost-realignment efforts.
4. Outlook and Revenue Growth Concerns
Analysts noted that while operational stability and expense control establish a solid foundation, Biogen requires new revenue growth drivers to sustain its turnaround and justify higher valuations next year.